Citations

Mayo Clinic

Showing 10 of 108585 citations.

Recurrent Pleomorphic Xanthoastrocytoma Presenting With Diffuse Leptomeningeal Spread
Grigsby-Rocca, Giovanna , Bermudez, Camilo , White, Jessica D. , Neth, Bryan J. , Uhm, Joon H. , Mustafa, Rafid , Neth, Byran J. , Mustafa, Rafid , White, Jessica D.

The Neurohospitalist | October 12, 2023 | Volume: 14 | Issue: 1 | Pages: 110-111

10.1177/19418744231207150 | PMID 38235026 Get It

We report a case highlighting key clinical, CSF, and imaging findings of recurrent pleomorphic xanthoastrocytoma with leptomeningeal spread.
Pulmonary hemodynamics and transplant‐free survival in sarcoidosis‐associated pulmonary hypertension: Results from an international registry
Gayen, S. , Baughman, Robert P. , Nathan, Steven D. , Wells, Athol U. , Alhamad, Esam H. , Culver, Daniel A. , Barney, Joseph B. , Carmoma, Eva M., Cordova, Francis , Huitema, Marloes P. , Scholand, Mary Beth , Ganesh, Sivagini, Birring, Surinder S. , Wort, Stephen J. , Shlobin, Oksana A. , Gayen, Shameek K , Kouranos, Vasileios , Wijsenbeek, Marlies , Price, Laura , Gupta, Rohit

Pulmonary Circulation | October 12, 2023 | Volume: 13 | Issue: 4 | Pages: No page available

10.1002/pul2.12297 | PMID 37840561 Get It

AbstractPulmonary hypertension (PH) is a risk factor for mortality in patients with sarcoidosis. Severe PH in chronic lung disease has previously been defined as mean pulmonary arterial pressure (mPAP) ≥ 35 mmHg or mPAP 25 ≥ mmHg with cardiac index (CI) ≤ 2 L/min/m2. However, there is no clear definition denoting severity of sarcoidosis‐associated PH (SAPH). We aimed to determine pulmonary hemodynamic cut‐off values where transplant‐free survival was worse among patients with SAPH. This was a retrospective cohort analysis of the Registry of SAPH database focusing on pulmonary hemodynamic predictors of transplant‐free survival among patients with precapillary SAPH. Cox regression was performed to determine which pulmonary hemodynamic values predicted death or lung transplantation. Kaplan−Meier survival analysis was performed on statistically significant predictors to determine pulmonary hemodynamic cut‐off values where transplant‐free survival was decreased. Decreased transplant‐free survival occurred among SAPH patients with mPAP ≥ 40 mmHg and SAPH patients with pulmonary vascular resistance (PVR) ≥ 5 Woods units (WU). Transplant‐free survival was not decreased in patients who fulfilled prior criteria of severe PH in chronic lung disease. We identified new cut‐offs with decreased transplant‐free survival in the SAPH population. Neither cut‐off of mPAP ≥ 40 mmHg nor PVR ≥ 5 WU has previously been shown to be associated with decreased transplant‐free survival in SAPH. These values could suggest a new definition of severe SAPH. Our PVR findings are in line with the most recent European Society of Cardiology/European Respiratory Society guideline definition of severe PH in chronic lung disease.
What is the role of the clinical microbiology laboratory in the care of diagnostically challenging OPAT patients? Illustrative cases and literature review
Nori, Priya , Thwe, Phyu M. , Mogollon, Jaime, Bartash, Rachel , Bolkent, Musa, Patel, Robin , Patel, Robin , Nori, Priya , Szymczak, Wendy A. , Orner, Erika P. , Bolkent, Musa Gökalp

Therapeutic Advances in Infectious Disease | October 12, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/20499361231205092 | PMID 37842169 Get It

Optimal care of patients requiring long-term outpatient parenteral or oral antimicrobial therapy by infectious diseases (ID) specialists is facilitated by an accurate microbiologic diagnosis. Close collaboration between ID specialists and the clinical microbiology laboratory for routine or specialized molecular testing can result in more accurate diagnoses, streamlined antimicrobial regimens, and improved patient outcomes.
Risk factor profile and outcomes of premature acute coronary syndrome after percutaneous coronary intervention: A 1‐year prospective design
Fallahzadeh, Aida , Mehraban, Saghar, Mahmoodi, Tara , Sheikhy, Ali , Aein, Afsaneh, Rafiee, Hamed , Mehrani, Mehdi , Sadeghian, Saeed , Naderian, Mohammadreza , Masoud-Kabir, Farzad , Hosseini, Kaveh , Tajdini, Masih

Clinical Cardiology | October 12, 2023 | Volume: 47 | Issue: 1 | Pages: No page available

10.1002/clc.24170 | PMID 37818995 Get It

AbstractBackgroundThe prevalence of acute coronary syndrome (ACS) among young adults (premature ACS) has dramatically increased in recent years, especially in developing countries. Yet, the data on these patients' attributed risk factors and outcomes are inconsistent. In this study, we aimed to investigate these data in a cohort of premature ACS cases who underwent percutaneous coronary intervention (PCI) compared to older patients.HypothesisWe hypothesize that premature ACS patients undergoing PCI will exhibit different risk factor profiles and outcomes compared to non‐premature patients. specifically, we anticipate that premature patients do not necessarily have better outcomes than non‐premature.MethodsOverall, 3142 and 10 399 patients were included in premature and non‐premature groups, respectively. Patients' pre‐operative, post‐operative, and follow‐up data were retrieved retrospectively from the Tehran Heart Center PCI databank.ResultsThe mean age of premature and non‐premature cohorts was 48.39 and 67 years, respectively. Patients were predominantly male in both groups. Family history of coronary artery disease (CAD), dyslipidemia, smoking, and opium addiction were more prevalent among the younger cohort. After adjustment, in‐hospital mortality in younger patients was considerably higher, with all‐cause mortality and major cardiovascular and cerebrovascular events (MACCE) exhibiting no noticeable difference among the two groups.ConclusionsRisk factor profile is different in young patients, and traditional cardiovascular risk factors, such as hypertension and diabetes mellitus, are more prevalent among older adults. Younger age is not equivalent to a better prognosis; hence, similar or even more caution should be taken into consideration regarding secondary prevention for these patients.
Systolic anterior motion of a transatrial transcatheter mitral valve replacement causing left ventricular outflow tract obstruction
Afoke, Jonathan , Crestanello, Juan A.

Perfusion | October 12, 2023 | Volume: 39 | Issue: 8 | Pages: 1740-1742

10.1177/02676591231206526 | PMID 37823304 Get It

Transatrial transcatheter mitral valve replacement is a hybrid strategy involving placing the patient on cardiopulmonary bypass and direct implantation of a transcatheter valve in a calcified annulus for mitral annular calcification. We report a rare phenomenon of systolic anterior motion of the leaflets of a transcatheter heart valve prosthesis used for mitral valve replacement causing left ventricular outflow tract obstruction. Although reported in transcatheter mitral valve replacement, we believe this is the first report of left ventricular outflow tract obstruction after transatrial mitral valve replacement and discuss the pre-disposing risk factors.
Early‐onset diabetes mellitus as a presenting feature of Werner's syndrome in an Indian family
Hoff, Fieke W. , Xing, Chao , Simha, Vinaya , Agarwal, Anil K. , Zhang, Xunzhi , Lekkala, Leena, Vaishnav, Madhumati S. , Vuitch, Frank, Garg, Abhimanyu , Xing, Chao

Molecular Genetics & Genomic Medicine | October 12, 2023 | Volume: 12 | Issue: 1 | Pages: No page available

10.1002/mgg3.2299 | PMID 37815015 Get It

AbstractBackgroundDiabetes mellitus (DM) in children and adolescents is typically caused by type 1 DM, followed by type 2 DM and maturity‐onset diabetes of the young (MODY). We report an unusual Asian Indian family in which three members presented with DM at ages 15, 20, and 30, but not fitting the typical clinical picture of type 1 DM, type 2 DM, or MODY. The primary objective was to elucidate the molecular genetic basis of DM in this family.MethodsThe proband, a 22‐year‐old man, had short stature, gray hair, osteoporosis, and markedly reduced subcutaneous fat on the body, especially on the extremities along with acanthosis nigricans, and developed myxoid malignant peripheral nerve sheath tumor. Detailed family history revealed multiple loops of consanguinity. The proband underwent whole‐genome sequencing, and seven relatives underwent whole‐exome sequencing.ResultsThe proband and three additional family members were found to have the homozygous c.561A>G nucleotide variant of WRN RecQ‐like helicase (WRN) gene consistent with the diagnosis of Werner's syndrome. The c.561A>G variant induces a new splicing site on exon 6 resulting in a truncated WRN protein, p.Lys187Trpfs*13.ConclusionOur report brings to attention the onset of DM during childhood or early adulthood in patients with Werner's syndrome who typically develop type 2 DM around the age of 30–40 years. Presence of consanguinity among parents, dysmorphic features, and malignancy should prompt consideration of diagnosis of Werner's syndrome.
Point-of-Care Ultrasound in Detection, Severity and Mechanism of Significant Valvular Heart Disease and Clinical Management
Wen, Songnan , Naqvi, Tasneem Z. , Naqvi, Tasneem Z

Journal of Clinical Medicine | October 12, 2023 | Volume: 12 | Issue: 20 | Pages: 6474

10.3390/jcm12206474 | PMID 37892613 Get It

Background: Early diagnosis of significant valvular heart disease (VHD) enables appropriate implementation of the best therapeutic strategy and follow-up. Cardiac auscultation remains suboptimal in early detection of VHD. The aim of this study was to evaluate the utility of point-of-care ultrasound (POCUS) for early detection of VHD and its severity. Methods: All consecutive patients with VHD who did not have a standard echocardiogram prior to first outpatient cardiology consultation underwent history and physical examination followed by POCUS study by an experienced physician in a general cardiology clinic from June 2017 to August 2022 at our institution. Subsequent standard transthoracic echocardiography (sTTE) was performed as the gold standard. Comparison was performed between POCUS and sTTE for the presence and severity of VHD. sTTE was performed by registered cardiac sonographers and interpreted by another cardiologist blinded to the POCUS results. Results: A total of 77 patients were studied (ge 72 ± 11 years, 58.4% males). A total of 89 significant valvular abnormalities were diagnosed. There were 39 (43.8%) cases of regurgitant VHD, 16 (18.0%) of stenotic VHD and 34 (38.2%) had evaluation for prosthetic valve function. The sensitivity (90.9%; 82.4%; 83.3%; 100%) and specificity (100%; 96.7%; 100%; 100%) were high for detecting ≥ moderate aortic regurgitation (AR), mitral regurgitation (MR), aortic stenosis (AS) and prosthetic valvular abnormality, respectively. The weighted κ coefficient between POCUS and sTTE for the assessment of ≥ moderate MR, AR and AS was 0.81 (95% CI, 0.65–0.97), 0.94 (95% CI, 0.84–1.00) and 0.88 (95% CI, 0.76–1.0), respectively, indicating excellent agreement. Conclusions: POCUS can identify patients with significant VHD and may serve as a powerful screening tool for early detection of significant VHD in the outpatient clinical practice with downstream impact on clinical management of significant VHD.
Immunosuppression is a risk factor for worse survival and disease‐specific death in cutaneous squamous cell carcinoma
Greene, Adina , Hwang, Angelina , Kechter, Jacob , Boudreaux, Blake W., Bhullar, Puneet , Severson, Kevin J. , Butterfield, Richard , Zhang, Nan , Tolaymat, Leila , Ochoa, Shari A. , Arpey, Christopher J., Baum, Christian L. , Mangold, Aaron R. , Mangold, A R , Hwang, Angelina S , Degesys, Catherine A.

JEADV Clinical Practice | October 12, 2023 | Volume: 3 | Issue: 1 | Pages: 182-190

10.1002/jvc2.265 Get It

AbstractBackgroundPrevious literature on cutaneous squamous cell carcinoma (cSCC) suggests that the incidence, rate of metastasis, and tumour severity of cSCC are higher in immunosuppressed patients than in immunocompetent patients. However, current literature lacks an extensive comparison of cSCC clinical characteristics and outcomes in immunosuppressed patients.ObjectivesWe compared cSCC tumour characteristics and disease‐related outcomes to help guide the clinical management of immunosuppressed patients.MethodsWe conducted a retrospective review of histopathologic and clinical data from 935 cSCC cases (19.5% immunosuppressed) from the Mayo Clinic.ResultsImmunosuppression was associated with younger age (69.3 vs. 74.8 years old, p < 0.0001), male gender (78.6% vs. 67.2%, p = 0.003), and higher grade cSCC tumour characterized by moderate or poor differentiation (25.7% vs. 15.8%, p = 0.009; 9.2% vs. 7.2%, p = 0.009, respectively). No significant differences were found in other tumour characteristics, including clinical tumour dimension, Brigham and Women's Hospital tumour staging or cumulative risk of metastasis and recurrence. Immunosuppressed patients had an increased risk of disease‐specific death on univariate analysis (hazard ratio [HR] [95% confidence interval, CI] 2.05 [1.13–3.74], p = 0.0128). Overall survival in the immunosuppressed population was worse (adjusted HR [95% CI] 1.83 [1.42–2.35], p < 0.001) and, notably, solid organ transplant recipients had the lowest overall survival when stratifying immunosuppressed patients by immunosuppression type (HR [95% CI] 1.62 [1.17–2.24], p < 0.0001).ConclusionsIn our study, immunosuppression status was predictive of poor differentiation of tumours and a reduction in overall and cSCC‐specific survival. Current staging systems for cSCC do not include immunosuppression as a risk factor and incorporating immune status may be beneficial for accurate risk stratification.
Complementary and alternative medicine for long COVID: a systematic review of randomized controlled trials
Yang, Juan , Lim, Kia Hui , Lim, Kia Teng , Woods, Jeffrey , Mohabbat, Arya B. , Wahner‐Roedler, Dietlind L. , Bauer, Brent A. , Woods, Jeffrey T., Ganesh, Ravindra

Therapeutic Advances in Chronic Disease | October 12, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/20406223231204727 | PMID 37841213 Get It

Background: Complementary and alternative medicine (CAM) interventions are growing in popularity as possible treatments for long COVID symptoms. However, comprehensive analysis of current evidence in this setting is still lacking. Objective: This study aims to review existing published studies on the use of CAM interventions for patients experiencing long COVID through a systematic review. Design: Systematic review of randomized controlled trials (RCTs). Methods: A comprehensive electronic literature search was performed in multiple databases and clinical trial registries from September 2019 to January 2023. RCTs evaluating efficacy and safety of CAM for long COVID were included. Methodological quality of each included trial was appraised with the Cochrane ‘risk of bias’ tool. A qualitative analysis was conducted due to heterogeneity of included studies. Results: A total of 14 RCTs with 1195 participants were included in this review. Study findings demonstrated that CAM interventions could benefit patients with long COVID, especially those suffering from neuropsychiatric disorders, olfactory dysfunction, cognitive impairment, fatigue, breathlessness, and mild-to-moderate lung fibrosis. The main interventions reported were self-administered transcutaneous auricular vagus nerve stimulation, neuro-meditation, dietary supplements, olfactory training, aromatherapy, inspiratory muscle training, concurrent training, and an online breathing and well-being program. Conclusion: CAM interventions may be effective, safe, and acceptable to patients with symptoms of long COVID. However, the findings from this systematic review should be interpreted with caution due to various methodological limitations. More rigorous trials focused on CAM for long COVID are warranted in the future.
FIGO statement: Fertility preservation
Henry, Laurie , Berek, Jonathan S. , Díaz, Ivonne, Feldberg, Dov , Niederberger, C. Craig, Ohlander, Samuel , Purandare, Nikhil , Rosenwaks, Zev, Wilailak, Sarikapan , Malhotra, Jaideep , Mocanu, Edgar V. , Niederberger, Craig, Tulandi, Togas , Wasson, Megan

International Journal of Gynecology & Obstetrics | October 12, 2023 | Volume: 163 | Issue: 3 | Pages: 790-794

10.1002/ijgo.15187 | PMID 37807831 Get It

AbstractFertility preservation is a growing field in reproductive medicine that may raise ethical questions. Preservation of fertility must be discussed with the patient if gonadotoxic treatment is required, whether in the case of benign or malignant pathology, or in the management of transgender identity. As a result, surgery or chemotherapy that has fewer adverse impacts on fertility should be proposed if this does not alter the prognosis of the disease. If the risk of infertility persists, then fertility cryopreservation should be proposed for children and adults of reproductive age. Sperm, oocytes, and gonadal tissue can be cryopreserved for many years. FIGO wishes to emphasize the importance of fertility preservation in the medical and surgical management of patients, and the importance of a specialized, multidisciplinary approach.